Neuronetics (NASDAQ: STIM) Files 8-K with Preliminary Financial Information

Neuronetics, Inc. recently submitted a Form 8-K with the Securities and Exchange Commission (SEC) on January 13, 2025, disclosing certain preliminary financial details for the periods ending December 31, 2024. According to the report, the company issued a press release on the stated date, presenting this financial information.

The company’s press release, attached as Exhibit 99.1 to the Form 8-K, is available for review by interested parties. It’s highlighted that the information provided, including the press release, does not constitute a filing under Section 18 of the Securities Exchange Act of 1934, nor is it incorporated into Neuronetics’ previous or upcoming filings with the SEC, except as expressly indicated in those filings.

Additionally, in compliance with Item 7.01 of the Form 8-K, the company made a Regulation FD Disclosure on the same date. Neuronetics shared a presentation with potential investors, known as the “Presentation,” which is filed as Exhibit 99.2. Similar to the financial information, the content of the Presentation is not considered a part of any future SEC filings, except where explicitly referenced.

The “Safe harbor” statement included in the filing underscores caution regarding forward-looking statements in the Current Report. The company advises against undue reliance on these statements due to the inherent risks and uncertainties that could lead to actual results differing significantly from projections.

Furthermore, the Form 8-K outlines key growth initiatives and financial milestones for Neuronetics in the coming period. The document indicates strategic synergies and cost savings following the company’s recent activities in the financial report. Neuronetics’ financial outlook suggests a target revenue range for fiscal year 2025, alongside operational and profitability forecasts.

Investors and stakeholders are encouraged to access the complete Form 8-K filing on the SEC’s website, www.sec.gov, to review detailed financial data and disclosures related to Neuronetics’ recent activities. As per regulatory requirements, the company commits to updating shareholders only as necessary and mandated by law, with no obligation to provide continuous updates on the furnished information.

The disclosure concludes with a list of exhibits attached to the filing, including the press release and the strategic update presentation, offering additional insights into Neuronetics’ operations and prospects moving forward. The document is signed and dated by Stephen Furlong, EVP, Chief Financial Officer, and Treasurer of Neuronetics, Inc.

As outlined within the filing, Neuronetics remains focused on transparent disclosure practices and prudent financial strategies in the competitive healthcare landscape. Stakeholders are advised to stay informed through official channels and regulatory filings to track the company’s progress closely.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Neuronetics’s 8K filing here.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.